CovidShiny: An Integrated Web Tool for SARS-CoV-2 Mutation Profiling and Molecular Diagnosis Assay Evaluation In Silico
Author:
Ma Shaoqian1ORCID, Xiao Gezhi1, Deng Xusheng1, Tong Mengsha1, Huang Jialiang1, Li Qingge1, Zhang Yongyou12ORCID
Affiliation:
1. The State Key Laboratory of Cellular Stress Biology, National Institute for Data Science in Health and Medicine Engineering, Research Center of Molecular Diagnostics of the Ministry of Education, School of Life Sciences, Xiamen University, Xiamen 361100, China 2. Faculty of Medicine and Life Sciences, Xiamen University, Xiamen 361100, China
Abstract
The coronavirus disease 2019 (COVID-19) pandemic is still ongoing, with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continuing to evolve and accumulate mutations. While various bioinformatics tools have been developed for SARS-CoV-2, a well-curated mutation-tracking database integrated with in silico evaluation for molecular diagnostic assays is currently unavailable. To address this, we introduce CovidShiny, a web tool that integrates mutation profiling, in silico evaluation, and data download capabilities for genomic sequence-based SARS-CoV-2 assays and data download. It offers a feasible framework for surveilling the mutation of SARS-CoV-2 and evaluating the coverage of the molecular diagnostic assay for SARS-CoV-2. With CovidShiny, we examined the dynamic mutation pattern of SARS-CoV-2 and evaluated the coverage of commonly used assays on a large scale. Based on our in silico analysis, we stress the importance of using multiple target molecular diagnostic assays for SARS-CoV-2 to avoid potential false-negative results caused by viral mutations. Overall, CovidShiny is a valuable tool for SARS-CoV-2 mutation surveillance and in silico assay design and evaluation.
Funder
Xiamen University Special Research Fund for SARS-CoV-2 Fundamental Research Funds for the Central Universities national undergraduate training program for innovation and entrepreneurship
Subject
Virology,Infectious Diseases
Reference61 articles.
1. WHO (2023, July 18). Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/. 2. Davis-Gardner, M.E., Lai, L., Wali, B., Samaha, H., Solis, D., Lee, M., Porter-Morrison, A., Hentenaar, I.T., Yamamoto, F., and Godbole, S. (2022). mRNA bivalent booster enhances neutralization against BA.2.75.2 and BQ.1.1. bioRxiv. 3. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster;Kurhade;Nat. Med.,2023 4. Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1;Miller;N. Engl. J. Med.,2023 5. Planas, D., Bruel, T., Staropoli, I., Guivel-Benhassine, F., Porrot, F., Maes, P., Grzelak, L., Prot, M., Mougari, S., and Planchais, C. (2022). Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies. bioRxiv.
|
|